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ABSTRACT 
Objective: The objective of this current study is to fabricate ocuserts to control the drug release from chosen bioadhesive polymeric matrixes to 
enhance patient compliance. Ciprofloxacin HCl (CFX HCl) was selected as a model drug.  
Methods: Different bioadhesive polymers with different film forming capabilities namely Hydroxy Propyl Methyl Cellulose (HPMC K4M), Poly Vinyl 
Alcohol (PVA), Sodium Carboxy Methyl Cellulose (Na CMC), Hydroxy Propyl Cellulose (HPC), Sodium Alginate (Na Alg.), pullulan and Xanthan Gum 
(XG) in different ratios were used in fabricating ocuserts using solvent-casting technique. Propylene Glycol (PG) was used as a plasticizer to 
facilitate the fabrication process. Characterization tests of the developed ocuserts were performed as well as bioadhesive tests and in vitro release 
studies of the incorporated drug. The obtained results were analysed using different release kinetic models. Stability of the selected ocuserts was 
investigated at 40±0.5 °C and 75±5% Relative Humidity (RH) for three months’ storage period. In vivo ocular irritation test was performed to 
investigate the safety of the formula in rabbits’ eyes as well as to test the release profile and thus to estimate In vitro In vivo correlation.  
Results: All the prepared ocuserts showed the uniformity of film characterization and bioadhesion strength ranged from 240±66 and 
158±52dyne/cm2. Selected formula from the in vitro release study tested for in vivo study showed the slow release of ciprofloxacin drug up to 24 h 
with no signs of eye irritancy. Results for In vitro In vivo correlation showed an excellent correlation with R2 
Conclusion: PVA based ocuserts proven to be a promising once-daily, effective and safe ocular delivery system of the drug. 
value of 0.9982.  
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Eye is an essential organ with unique qualities and enable us to see 
the world. Drug delivery through ocular route is local more than 
systemic to bypass the high blood concentration of the drug, which 
may cause eye damage [1]. 
The solitary anatomy, biochemistry, and physiology of the eye 
challenge the formulator to circumvent the protective barriers of the 
eye without causing any tissue damage because of the impervious 
nature of the eye [2]. About 70% of the total ophthalmic preparations 
available in market are conventional ophthalmic dosage forms (eye 
drops and ointments). For these dosage forms, frequent dosing is the 
net result of the availability of just a little amount for its therapeutic 
effect. That’s why to overthrow these issues, newer pharmaceutical 
technologies such as iontophoresis, nanoparticles, liposomes, 
nanosuspension, microemulsion, in situ gel and bioadhesive ocuserts 
have been developed to improve patient compliance by increasing the 
bioavailability of the drug in a controlled and sustained manner [3–6]. 
Ocuserts (synonyms of Ocular inserts) are drug delivery devices 
constructed from polymeric materials with solid or semi-solid 
consistency, delivering the incorporated drug to the ocular surface 
by placing it in the conjunctival sac. Ocuserts demonstrate many 
advantages such as delivering an accurate dose, minimizing systemic 
drawbacks of ocular remedies, prolong the ocular residence time 
thus reducing the frequency of administration leading to improving 
patient compliance, possibility of releasing drugs at a slow and 
constant rate which from an industry point of view, could increase 
shelf life stability [7]. Ocular route provides large absorption surface 
area and high vascularization offering good penetration for 
hydrophilic, low molecular weight drugs achieving fast onset of 
action [8]. Compared to oral delivery, the ocular administration 
provides a potential of dose reduction because it avoids the hepatic 
first pass metabolism. Therefore, in emergency therapy, ocular 
administration of convenient drugs would be considered as an 
alternative to other administration routes [9]. 
Ocuserts applied behind the eyelid were found to prolong the 
retention time and precision of dosing [10]. However, films were 
found to tend to move across the surface of the eye, thus resulting in 
irritation. It has been shown that the addition of mucoadhesive 
polymers to ocular films, which can adhere to the epithelial surface 
[11] reduced film movement across the eye, minimizing ocular 
irritation and burning sensations [12]. The main disadvantage 
reported for ocuserts is the annoying sensation accompanied its 
insertion in the eye, but the numerous advantages of ocuserts 
supersede this single disadvantage [13] as seen by the implementation 
of this technology in several successfully marketed ocuserts (Ocusert®, 
Ocufit®SR, and Minidisc®
Many ocular regions have poor accessibility to systemic circulation due 
to the presence of protective barriers which makes the local delivery via 
topical administration is the favoured route for the treatment of ocular 
diseases. Typical conditions that require ocular administration include 
ocular infections and disorders (like conjunctivitis and glaucoma) [2].  
) [14]. 
CFX HCl is a broad-spectrum fluoroquinolone antibiotic that can be 
taken orally or intravenously [10]. 
CFX HCl is used systematically in numerous microbial 
contaminations such as dermal, pulmonary, urinary tract infections 
and topically in conjunctivitis and anterior ocular infections [15].  
CFX HCl was the most used antibacterial agent worldwide, and the 
fifth regularly used generic antibacterial in the USA during the last 
decade in the 20th
The aim of the current study was to develop bioadhesive ocuserts 
for the topical delivery of CFX HCl suitable for a once a day 
application employing different bioadhesive polymers. 
 century [16]. 
MATERIALS AND METHODS 
Materials 
CFX HCl was a gift sample from Eipico, Egypt. Pullulan was purchased 
from VWR International LLC, West Chester, PA, USA. HPC, HPMC K4M, 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 10, Issue 6, 2018 
Dawaba et al. 
Int J App Pharm, Vol 10, Issue 6, 2018, 309-317 
310 
PG, and Glycerin were obtained from ADWIC, El-Nasr Chemical Co., 
Cairo, Egypt. Na Alg., Di-Sodium Hydrogen Phosphate (Na2HPO4) and 
Potassium Di-Hydrogen Phosphate (KH2PO4
Drug identification and detection of any possible incompatibility 
existed between the excipients is done through Fourier transform 
infrared (FTIR) spectroscopy. CFX HCl powder and the formula (F-I) 
blend were examined using FTIR spectrophotometer (model Impact 
410, Milwaukee, WI, USA) with a scanning range 500 to 4000 cm
) were supplied from El-
Nasr pharmaceuticals company, Cairo, Egypt. Na CMC and PVA were 
supplied from Sigma Company for pharmaceuticals, Cairo, Egypt and 
were used without further purification. 
Methods 
UV scanning solution preparation 
A stock solution of CFX HCl was prepared by placing accurately 
weighed 100 mg in a 100 ml measuring flask and freshly prepared 
phosphate buffer pH 7.4was added till reaching the mark. From the 
resultant solution, 1 ml was taken and completed to 100 ml with 
phosphate buffer pH 7.4 and then scanned in the 200-400 nm using 
a UV-spectrophotometer (Shimadzu UV spectrophotometer, 1601-
PC double-beam spectrometer, Kyoto, Japan).  
FTIR spectroscopy 
–1 
and the resolution was 1 cm–1
Fabrication of ocuserts 
. KBr disk method was used to obtain 
the FTIR spectra of CFX HCl and the formulation (F-I) blend. The 
infrared peaks of pure CFX HCl were analysed and compared with 
the peaks obtained for the formulation (F-I) blend to identify if there 
is the deletion of or additional formation of peaks. 
CFX HCl ocuserts were prepared by solvent casting technique using 
HPMC K4M, pullulan, CMC, HPC, Na Alg., PVA and XG as 
biodegradable bioadhesive polymers [17, 18]. All polymers were 
completely dissolved in distilled water (left overnight for uniform 
dispersion) except PVA which was dissolved in hot water at 70 °C. 
After dissolving the polymers in water, PG as a plasticizer was added 
(2.5% w/w of polymer). Bath sonicator (Model SS101H 230, Sonix 
IV, CA, USA) was used to remove air bubble appeared after addition 
of CFX HCl into the polymeric solution. After complete mixing of 
drug and polymer, 10 ml of the clear solution was poured into the 
clean petridish moistened with glycerin. The petri dish was covered 
with an inverted glass funnel of stem orifice 0.6 cm in diameter with 
a cotton plug closing the stem of the funnel. Clearance was provided 
for the escape of the solvent vapors by raising the base of the funnel 
(2 cm) just above the resting surface. The funnel was an aid to 
control the rate of evaporation of the solvent and reducing the 
blistering of the surface of the deposited film [19]. After complete 
evaporation of the solvent, cast films were obtained, cut into definite 
circular pieces by cork borer (8 mm), wrapped in an aluminum foil 
and stored in a CaCl2
  
 desiccator at room temperature in a dark place 
for further evaluation studies. 
Table 1: Formulation of ocuserts with the different film-forming agents
Formula code 
* 
HPMC K4M PVA CMC HPC Na Alg. Pullulan XG 
F-I 1.5%       
F-II  1.5%      
F-III   1.5%     
F-IV    1.5%    
F-V     1.5%   
F-VI      2%  
F-VII       1.5% 
*All formulae were prepared with 2.5% PG as a plasticizer and 17 mg of CFX HCl. 
 
Characterization of film fabrication  
The thickness of the ocusert was measured using a film thickness 
tester (Vernier caliper, Shanghai, China) at various regions of the 
film (n = 3) [20, 21]. 
Three films of the same size were weighed on an electronic digital 
balance (Mettler AJ 100, Switzerland). The average weight, as well as 
the weight variation, were calculated [20-22].  
Petri dish containing 0.5 ml distilled water was used to moisten the 
ocusert for 30 s. Then the pH meter electrodes (Digital pH meter, 
Toshniwal Pvt. Ltd., India) were brought in contact with the surface 
of the ocusert and left for 1 min for equilibration. The pH value was 
noted and recorded [20, 21].  
To determine moisture loss, weighted ocusert was placed in a 
desiccator containing anhydrous calcium chloride. After three days 
the film was reweighed, and moisture loss was calculated using the 
following equation [23, 24]. 
Moisture loss (%) = (Wi-Wf/Wi
Where W
) ×100 … (1) 
i is the initial weight, and Wf 
For Moisture gain study, weighted ocusert was placed in a desiccator 
containing 100 ml of saturated solution of aluminum chloride to 
maintain 80% humidity. After three days film was reweighed, and 
moisture gain was calculated using the following equation [23, 24]. 
is the final weight of the film. 
The study was done in triplicate for each ocusert formulation.  
Moisture gain (%) = (Wf-Wi/Wi
Where W
) ×100 …. (2) 
i is the initial weight, and Wf 
Folding endurance was determined manually in triplicate by 
repeatedly folding an ocusert at the same place by using forceps till 
broken. The numbers of folding the ocusert without being broken 
were calculated, and the standard deviation (SD) was estimated [24].  
is the final weight of the film. 
The study was done in triplicate for each ocusert formulation.  
Drug content was analysed by dispersing the ocusert in 20 ml of 
freshly prepared phosphate buffer pH 7.4. The solution was stirred 
and filtered through Whatman filter paper no 1. About 1 ml solution 
was withdrawn, suitably diluted with phosphate buffer pH 7.4 and 
the drug content in the solution was measured by a UV-Visible 
spectrophotometer (Shimadzu UV spectrophotometer, 1601-PC 
double-beam spectrometer, Kyoto, Japan) at λmax
 
 278 nm [23, 24]. 
 
Fig. 1: Schematic diagram of the device used for bioadhesion test 
(A) modified-balance (B) weight (C) rubber stopper (D) cornea 
with ocusert (E) glass vial (F) support to the vial to adjust weight 
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Bioadhesion characterization 
Ex vivo bioadhesive strength 
The freshly excised cornea of a cow was used as a model mucous 
membrane for the measurement of bioadhesive strength. Fresh cow 
cornea was obtained from a local slaughterhouse and used within 2 h of 
slaughter. The mucosal membrane was separated by removing the 
underlying fat and loose tissues. The membrane was washed with 
distilled water and then with isotonic phosphate buffer pH 7.4 at 37 °C. 
The bioadhesive strength of ocusert (n = 3) was measured on a 
modified two-arm physical balance as illustrated in fig. 1 [25, 26]. 
The pan at the left arm of the balance was detached, and a vertical thread 
was tied to its end. A rubber stopper, hanging downward, was hung to 
the lever of the left arm. The ocusert to be tested adhered to the 
downward facing side of the rubber stopper. Cow cornea was tied onto 
the open mouth of a glass vial filled with isotonic phosphate buffer. The 
vial was fitted in the centre of a glass beaker fill illustrated ed with 
simulated tear fluid (STF) with pH 7.4, 37 °C±1 °C. The apparatus was set 
such that the vial (mucosal membrane tied on it, facing upward) lies 
exactly below the rubber stopper (patch adhered onto it, facing 
downward). The rubber stopper was lowered so as to make the ocusert 
come in contact with the membrane. After facilitating the contact 
between the two, weight was put on the right limb of balance and 
increased gradually until the ocusert got detached from the cornea. The 
weight (gram force) required to detach the ocusert from the mucosal 






where w is the weight required for the detachment of ocusert, g is 
the acceleration due to gravity considered as 980 cm/s, and A is the 
area of the mucosal surface exposed (cm2) [25–27]. 
Ex vivo bioadhesion time 
The ex vivo bioadhesion time was ascertained (n = 3) after 
application of the ocusert onto freshly cut cow cornea. The fresh 
cornea was fixed in the inner side of the beaker, above 2.5 cm from 
the bottom, with cyanoacrylate glue. One side of each ocusert was 
wetted with one drop of isotonic phosphate buffer pH 7.4 and pasted 
to the cornea by applying a light force with a fingertip for 30 s. The 
beaker was filled with 500 ml of STF pH 7.4 and was kept at 37 °C±1. 
Ocusert adhesion was monitored up to 6 h and the time required for 
the ocusert to detach from the cornea was recorded as the 
mucoadhesion time [25–27]. 
In vitro drug release study 
The in vitro drug diffusion from the ocuserts was studied using the 
cylindrical glass tube (Internal diameter 15 mm and length 100 mm). 
The diffusion cell membrane (Prehydrated cellophane membrane) 
was tied to one end of the cylindrical tube, which acted as a donor 
compartment and the ocusert was placed inside this compartment. 
The entire surface of the membrane was in contact with 25 ml isotonic 
phosphate buffer (pH 7.4) placed in a 50 ml beaker (receptor 
compartment). Shaking water bath (FALC Model WB-MF, FALC 
instrument, Italy) was used to shake the contents of the receptor 
compartment continuously at constant temperature (37±0.5 °C). At 
definite time intervals (1 h), 1 ml of the release solution was 
withdrawn from the receptor compartment and replaced with freshly 
prepared phosphate buffer (pH 7.4). The aliquot solution was analysed 
for the drug content using UV-Visible spectrophotometer (Shimadzu 
UV spectrophotometer, 1601-PC double-beam spectrometer, Kyoto, 
Japan) at λmax 278 nm [23, 24]. 
Drug release kinetic study 
To determine the exact mechanism of drug release from the 
ocuserts, the in vitro drug release data obtained was analysed using 
Zero order, First order and Higuchi square root equation [28, 29]. 
Stability study  
Accelerated stability studies might serve as a tool for formulation 
screening and stability issues related to shipping or storage at room 
temperature [30]. 
The accelerated stability studies were carried out in accordance with 
the ICH guidelines [31]. Enough ocuserts (packed in aluminium foil) 
were stored, with RH of 75 % and at a temperature of 40±0.5 °C for 
three months. The samples were tested for drug content after 0, 7, 
15, 30 and 90 d respectively. 
In vivo ocular irritation test  
Approval for the use of animals in the study was obtained from the 
Al-Azhar University, Faculty of Pharmacy, Animal Ethics Committee 
(Ref. No.166/2018) which comply with the 3ARRIVE guidelines. The 
current experiment was carried out in accordance with the U. K. 
Animals (Scientific Procedures) Act, 1986 and associated guidelines, 
EU Directive 2010/63/EU for animal experiments. In addition, all 
institutional and national guidelines for the care and use of 
laboratory animals were followed. 
Our in vivo study aims to determine the objective irritation potential 
of the prepared ocusert and the in vivo drug profile of the selected 
ocusert. The rabbit was chosen as a model for this study because its 
eye simulates an adult human eye with respect to size, shape, 
physiology, and composition of tears (32). 
New Zealand rabbits of either sex weighing 2.5 to 3.5 kg were used 
to measure the in vivo ocular irritation test in the eye. The rabbits 
were purchased from the Nile Company for pharmaceuticals and 
chemical industries (Al Sawah St, Cairo, Egypt).  
The animals were housed in cages in the animal house (located in 
the faculty of pharmacy (boys branch), Al-Azhar university, Cairo, 
Egypt) under controlled conditions of temperature (27±2C) and 
light. They were fed with standard laboratory diet, and water was 
provided ad libitum. Ethical clearance for the handling of 
experimental animals was obtained. The rabbits were fed balanced 
diet pellets and maintained in a temperature-controlled room, at 20 
°C to 24 °C before the experiment. 6 animals were used in the 
experiment where free leg and eye movement was allowed. The 
investigated ocusert was placed in the left eye while the right eye of 
each rabbit was considered the control. The ocusert was sterilized 
by using UV radiation before in vivo study. The ocuserts and other 
materials were exposed to UV radiation for 1 h [33]. After 
sterilization, ocusert was transferred into polyethylene bag with the 
help of forceps inside the sterilization chamber itself. The 
observations based on scoring approach (0 = normal; 3 = worst) 
according to Peyman scale. [34] Peyman et al., [34] established the 
safety of the developed ocuserts in the rabbit eye. Ocusert was 
removed each hour for the first eight hours to determine the amount 
of drug released and hence evaluate in vitro in vivo correlation. The 
amount of drug remaining in each ocusert was determined as per 
the assay method of the drug in ocuserts given in drug content. 
Cumulative percent drug released (CDR) in vivo was calculated [35, 
36] 
Sterility test 
Any preparation intended to be placed in the eye must be sterile, 
therefore, testing the sterility is a very important evaluation 
parameter. The tests for sterility were done by detecting the presence 
of viable forms of bacteria, fungi, and yeast in or on preparations. The 
tests were carried out under strict aseptic techniques to avoid 
accidental contamination of the preparation [37]. 
The sterility test was performed according to the guidelines of 
Indian Pharmacopoeia applying direct inoculation method. 2 ml of 
prepared CFX HCl ocusert solution was removed with a sterile 
needle and aseptically transferred to Medium A (fluid thioglycollate 
medium) and Medium B (soyabean-casein digest medium) 
separately. After mixing with each medium, incubation of each 
medium for 7 d was done (The incubation temperature was 30 °C to 
35 °C in the case of fluid thioglycolate medium and 20 °C to 25 °C in 
the case of soyabean-casein digest medium) [37]. 
Microbiological studies 
Staphylococcus aureus (S. aureus; ATCC® 25923) test microorganism 
purchased from American Type Culture Collection (PO Box 1549, 
Manassas, VA 20108 USA) was used to assess the biological activity 
of the selected ocusert formulation. The test organism was seeded in 
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nutrient agar and allowed to solidify in the petri dish. An ocusert 
was carefully placed over the agar layer at a suitable distance [38]. 
The plates were then incubated at 37±0.5 °C for 24 h. After 
incubation, the obtained zone of inhibition was compared with the 
control ocusert (i.e. ocusert with no drug). 
RESULTS AND DISCUSSION 
UV scanning 
The stock solution was scanned in the 200-400 nm UV regions. The 
wavelength adopted for absorbance measurement was the observed 
wavelength maximum (λmax) at 278 nm. 
FTIR spectroscopy 
The characteristic absorption bands of CFX HCl at 1281.59 and 1612 
cm−1 (fig. 2b) was due to the stretching vibration of C–F bond and the 
vibration of phenyl framework conjugated to − COOH, respectively. 
The stretching vibration at 1705.07 cm −1was due to − COOH and the 
stretching vibrations of C–H from the phenyl framework at 2962.66 
and 2908.65 cm−1were also observed. All the peaks were also found 
in drug-loaded ocusert that confirms the presence of the drug in the 
polymers without any interaction. 
Fabrication of ocuserts 
Ocuserts were prepared using polymers pullulan, HPC, HPMC K4M, 
CMC, Na Alg., PVA and XG. The selection of polymers depended on 
their film-forming properties, their biodegradability and retardant 
to biodegradability to provide sustained release pattern. As shown 
in fig. 3, the prepared ocuserts were found to be satisfactory 
uniform, transparent and flexible [39]. 
 
Fig. 2: FT-IR spectra of the drug-loaded ocular insert of HPMC 
(a) and the CFX HCl (b)
 
 
Fig. 3: Photos representing the fabrication of ocuserts 
 
Characterization of the prepared ocuserts 
The prepared ocuserts were evaluated for their thickness at three 
random points. All ocuserts showed uniformity in thickness as 
indicated by low SD of the measured thickness. Variations in the 
ocusert thickness is reflected by the different amount of polymer 
needed for ocusert fabrication (table 2). 
Uniformity of the weight of the ocuserts is illustrated by low SD 
obtained after measurement. The mean weight value varied between 
2.44±0.15 mg to 8.4±1.3 mg, as it’s affected proportionally by the 
ocusert thickness. 
The mean values of three replicates of both % moisture loss and % 
moisture gain were recorded in table 2. Formulae F-V and F-VI 
become brittle upon exposure to moisture loss while formulae III 
and IV showed gelation of the film and in formula V disintegration of 
the film into fragments took place upon moisture gain. These 
observations are the net result of different hydration properties of 
different polymers. 
All prepared formulae showed uniform drug content in the range of 
94.14±8.22 % to 98.22±5.02 % with low SD values. 
Folding endurance of all batches was found between 19±6 to 
72±11, the significant difference in the folding endurance of the 
prepared films is due to the use of different polymer types and 
concentrations. 
The values of surface pH vary between 6.2 to 7.2 which give rise to 
the assumption that the ocuserts will cause no irritation upon 
insertion in the eye. 
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Moisture loss % Moisture gain % Drug content % Folding endurance Surface pH 
F-I 0.263±0.05 4.6±0.24 21.6±7.4 36.4±7.8 94.6±7.4 56±7 6.23 
F-II 0.34±0.02 8.4±1.3 24.8±6.6 33.2±11.4 97.04±4.6 72±11 6.2 
F-III 0.24±0.07 4.6±0.07 6.8±2.7 Gelation 98.22±5.02 45±6 6.22 
F-IV 0.22±0.00 4.9±0.63 12.8±3.3 Gelation 95.7±12.7 24±4 7.1 
F-V 0.31±0.04 5.7±0.05 Brittle Disintegrated 98.02±9.7 22±6 6.66 
F-VI 0.32±0.02 6.42±0.26 30.5±8.5 34.7±13.8 96.37±10.2 62±14 6.8 
F-VII 0.316±0.04 2.44±0.15 Brittle 35.4±11.2 94.14±8.22 19±8 7.2 
  (Results are expressed as mean±SD, n=3)٭
 
Bioadhesion characterization 
Ex vivo bioadhesion strength 
Bioadhesion may be defined as the adhesion between a polymer and 
a biological membrane, e. g. mucus. The strength of bio-adhesion is 
affected by numerous factors such as the molecular weight of 
polymers, contact time with mucus, swelling rate of the polymer, and 
biological membrane used in the study. All ocuserts showed 
appreciable bioadhesive detachment stress that ranged between 
240±66 and 158±52 dyne/cm2 (fig. 4) indicating a potential of 
sustaining the stay and enhancing contact with cornea. Various 
mechanisms have been proposed to explain the in vitro bioadhesion 
or mucoadhesion phenomena such as electrical double layers, 
electrostatic attractions, hydrogen bonding, Van der Waals force, 
hydrophobic bonding, wetting, diffusion-interpenetration, physical 
entanglements, and surface-free energy [40].  
Most of the hydrophilic polymers can absorb water and swell. This 
can increase the potential to adhere onto mucosal surfaces. This is 
the simplest mechanism of adhesion and has been defined as 
“adhesion by hydration”.  
Na CMC can increase surface charge density, and the carboxylic group 
can form hydrogen bonds with tissue [40]. HPMC is the long chained, 
non-ionic polymer and the mucoadhesive property could be due to the 
formation of physical or hydrogen bonding with the mucus 
components. HPMC can relieve the dryness and irritation even in the 
case of reduced mucus secretions [40, 41]. Na CMC and HPMC show 
faster hydration rate and thereby swelling which helps in the 
interpenetration of mucus and polymer resulting in bio-adhesion. 
HPMC is a non-ionic polymer containing only hydroxyl groups, 
which can form weak hydrogen bonds with mucous layers. 
Furthermore, owing to its slow rate of hydration it can form a strong 
surface gel that efficiently adheres onto the mucosal surface and 
remains in contact for a longer time. For this reason, it can be 
characterized as one of the most effective mucoadhesive polymers 
[25, 42].  
The highest bioadhesive force showed by F-IV containing HPC while 
the lowest value showed by F-VI containing pullulan. 
 
 
Fig. 4: Histogram representing the bioadhesion force of 
different ocuserts, (Results are expressed as mean±SD, n=3) 
Ex vivo bioadhesion time 
The ex vivo bioadhesion time (residence time) of ocuserts varied 
from 2360±140 to 260±32 s. (fig. 5). It was observed that a 
gradual increase in the residence time occurred with a 
concomitant increase in the polymer viscosity. The observation 
can be assigned to the inherent property of the polymer HPMC 
that although showing significantly higher swelling is less water 
affined and hence tends to retain its structure better. In addition, 
increased viscosity led to the formation of a surface gel that 
maintained its structural integrity for a longer period of time, 
thereby resulting in increased residence time. 
 
 
Fig. 5: Histogram representing the bio-adhesion time of 
different ocuserts. (Results are expressed as mean±SD, n=3) 
 
In vitro drug release study 
The cumulative percent of CFX HCl released from ocuserts as a 
function of time is shown in Fig. 6 which revealed that 99% of the 
drug was released from HPMC based ocuserts in about 5 h. 
Na Alg. and pullulan based ocuserts showed very close results (i.e. 
Na Alg. based ocuserts released about 94% and pullulan based 
ocuserts released about 92% in 8 h). 
PVA, HPC and XG based ocuserts released 98%, 92% and 90% 
respectively in about 24 h. The most sustaining effect is attained by 
Na CMC based ocuserts where it shows only the release of 34% in 
about 24 h.  
The enormous difference in drug release may be explained by the 
change in the polymer forming the ocuserts. Generally, drug release 
from the polymeric matrices is elicited by the ease of water 
accessibility into the matrix, which breaks the polymer-polymer 
bonds and thus simultaneously leads to bounding of water and 
polymer molecules, separation of polymer chains, swelling to form a 
gel, and finally dispersion of polymer chains in the medium. ''The 
drug dissolves in the gel and diffuses to the exterior with a rate 
depending on its concentration gradients and its diffusion ability 
through the gel. Concurrently, the latter is eroded with a rate 
depending on polymer molecular weight and hydrodynamics of 
release medium. The drug release pattern depends on the relative 
rates of these processes’’ [43]. 
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As, HPMC is a hydrophilic polymer which facilitates ease of water 
penetration into the polymer matrix and hence the ease of drug 
diffusion. Although pullulan is also hydrophilic polymer composed of 
polysaccharide, it shows more sustaining in drug release than HPMC 
due to a greater amount of pullulan is needed in fabricating 
satisfactory films other than HPMC where a lesser amount is 
sufficient in fabricating film with satisfactory mechanical strength. 
Na Alg. showed more retardation in drug release reached to 8 h to 
complete release of the incorporated drug. This may be explained by 
features of Na Alg. in which hydrophilic functional groups of the 
polymer and water molecules tend to bound together by hydrogen 
bonding leading to excessive swelling results in retarding of drug 
release [44].  
In case of PVA (a hydrophilic polymer); but in its processing in 
formulating a film, it was heated to 70 °C and plasticized by PG. Both 
heat and PG addition caused crosslinking of PVA resulting in 
retardation in drug release [45]. 
The release pattern of HPC can be explained by high swelling 
behavior which results into inclusion of water inside the polymer 
matrix resulting into retardation in drug release [46]. 
XG is considered a good matrix-forming material for sustained-
release tablets as it tends to form viscous gels in the presence of 
water, whether they are used alone or in combination with other 
gums or polymers. This property also affects the drug release from 
ocuserts as seen in the dissolution behaviour [46]. 
In case of Na CMC there was great retardation in drug release although 
its hydrophilic character it had great swelling behaviour and inclusion of 
water molecules into the polymer matrix results in the formation of gel 
into the polymer matrix causes retardation in drug release as seen the 
remaining of gel in the diffusion cell at the end of 24 h but it may be 
promising in preparing formulations for several days but in ocular route 
it may be annoying to the patient so its excluded from further study. 
By overviewing the aforementioned release pattern, F-II was selected as 
a promising ocuserts providing the overall incorporated drug in 24 h 
comply with the hypothesis of the study by formulating once a day dose. 
Considering the drug release kinetics when the data was plotted as 
cumulative % of the drug released vs. time according to zero order 
equation, F. I, VI and VII showed a fair linearity indicting higher 
correlation than first order and Higuchi equation, with the highest R2 
values compared to other plots, while, F. II, III, and IV showed a fair 
linearity with first order indicting higher correlation than zero order 
and Higuchi equation, with the highest R2 values compared to other 
plots except for Alginate showing diffusion release. The zero-order 
kinetics [47] reveals delivery of the drug in a sustained manner 
whereby the drug is held in a reservoir representing the ocusert and 
is released at a constant rate to provide a constant concentration in 
the cornea which provides improved patient compliance [48, 49]. 
 
 
Fig. 6: In vitro cumulative percent release of CFX HCl ocuserts, (results are expressed as mean±SD, n=3) 
 
Table 3: R2 correlation values of different kinetic models of CFX HCl ocuserts 
Formula R2 of zero R2 of first R2 of higuchi 
F-I 0.998568 0.82807 0.996927 
F-II 0.940915 0.99503 0.978563 
F-III 0.997076 0.99716 0.973945 
F-IV 0.943501 0.99489 0.972235 
F-V 0.990315 0.96156 0.999468 
F-VI 0.996656 0.96004 0.995587 
F-VII 0.99752 0.98684 0.97749 
 
Stability studies 
Formula F-II was subjected to accelerated stability study to 
determine the physical stability of the formulation. There were no 
significant changes regarding the physical properties at the end of 
the three months and drug content during the study period. The 
overall degradation is less than 1.25%. A tentative shelf-life of one 
year may be assigned to formulation as per ICH guidelines. No 
change in physical appearance of ocusert was reported during the 
period of study thus revealing that F II passed the stability test 
indicating that it was chemically, physically and microbiologically 
stable at the examined temperature for 3 mo. However, its shelf life 
needs to be established by further studies at different temperatures 
and humidity conditions.  
UV irradiation 
The efficiency of the sterilization process is indicated mainly by 
sterility test where the ocuserts is examined for sterility by two 
media where it showed no sign of turbidity after 7 d for Medium A 
(fluid thioglycollate medium) and Medium B (soyabean-casein digest 
medium) indicating excellent sterility of the tested ocuserts.  
In vivo drug release and irritation study 
The results of in vivo drug release study are presented in fig. 7. The 
ocusert for the first 5 h can be removed from the rabbit eye and tested 
for drug remaining. After the first 5 h the ocusert adhesive to the ocular 
surface and cannot be removed. The rabbits also examined for eye 
irritancy for 7 d after the study and no rabbit show any sign of irritancy 
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(score 0) for all formulations. The in vivo drug release study from F. II 
was found to be in accordance with that of the in vitro drug release study. 
Hence, we tried to correlate in vivo results with the in vitro percentage 
drug release. The correlation value was found to be 0.9982 [50]. 
Therefore, the formula (F-II) exhibited strong in vitro-in vivo 
correlation revealing the efficacy of the formulation (fig. 8). No drag 
out of circular inserts at the time of experiment was happened which 
suggest that the dimension (8 mm) was suitable as ocuserts [50]. 
 
 
Fig. 7: In vivo cumulative percent release of formula II, (results are expressed as mean±SD, n=3) 
 
 







Fig. 9: Sequence of photos of in vivo experiment showing (a) before insertion of ocusert (b) during removal of ocusert (c) and after the 
complete dissolving of ocusert after 24 h 
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Microbiological studies 
Testing the selected ocuserts (Formulae F-II and F-III) against staph 
aureus showed good antimicrobial activity indicted by clear zones of 
inhibitions (3 cm diameter for each formulae) when tested 
microbiologically on solidified agar. While control ocusert (ocusert with 
no drug) shows no zone of inhibition as represented in fig. 10 [51]. 
 
 
Fig. 10: Photo represents the microbiological study of formula II 
and III ocusert against S. Aureus 
 
CONCLUSION 
Various bioadhesive formulations of C F X HCl ocuserts were 
prepared using a solvent casting method and evaluated. Ocuserts 
(formula F-II) consisting of a 1.5% PVA with 2.5% PG satisfied all the 
pharmaceutical parameters of bioadhesive ocuserts and 
demonstrated controlled release of the drug in the eye over the 
period of 24 h. Formula F-II is considered a promising formulation 
suitable for a once a day dose and thereby improving the patient 
compliance by providing benefits of reducing in the frequency of 
administration by controlled drug release. Pharmacokinetics and 
pharmacodynamics studies in human beings are needed to be 
carried out to establish the therapeutic utility of this system. 
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